Dynamic assessment of considerations for intervention in those with either PMF or sMF in 2017. EPO, erythropoietin; ESA, erythroid-stimulating agent; HLA, human leukocyte antigen; PET, postessential thrombocythemia; PPV postpolycythemia vera.